HeartWare International competitors

Mike McMullen is Agilent’s CEO-elect. He will assume the CEO position in March 2015 when William (Bill) Sullivan takes an advisory role until his retirement. As a first step in the CEO transition, McMullen has been named president and chief operating officer. McMullen has more than 30 years of industry experience and senior management experience at Agilent. He has been president of the company’s Chemical Analysis Group (CAG) since 2009, a role he still fills on an acting basis. As head of CAG, McMullen transformed the business, consistently delivering market-leading growth and profits. He championed strategic acquisitions and architected Agilent’s China strategy. He built the Agilent-wide Services business that has now been made one of Agilent’s three major businesses. McMullen has extensive experience working across Agilent’s businesses, and is recognized for his inspirational leadership style. He also has significant international experience, having lived in Japan, leading Agilent’s Japan field sales and support operations, and later adding responsibility for China field operations. McMullen joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst. He holds a bachelor's degree in economics and business administration from the University of Delaware and an MBA from Wharton Business School.

Results-focused senior executive whose strategic vision, leadership and commitment to success consistently led to dynamic gains in revenue, profit, operational performance and competitive advantage in US and global markets. Leverages instinctive ability to zero in on product and market potential to achieve objectives in start-up, turnaround and growth environments.Selected Achievements:Led $400 million division to record growth in worldwide sales and profit, with 14% year-over-year revenue gains and 10 point improvement in the bottom line.Key member of executive team that negotiated the $2.2 billion acquisition of Gyrus ACMI by Olympus Corporation.Built US division to $96.6 million in sales with average annual revenue growth of 35% for 3 consecutive years.Strategic forward thinker - initiated and spearheaded a comprehensive $700 million business restructuring to comply with changing healthcare laws and regulations while concurrently streamlining process, driving productivity and increasing customer satisfaction. The initiative resulted in a 15% reduction in expenses and a 5% revenue increase.

Michael A. Mussallem, age 56, has been chairman and CEO of Edwards Lifesciences, Inc. since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mr. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor's degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Indiana.

Gary Guthart joined Intuitive Surgical in April 1996. Effective January 2010, Guthart was appointed as Chief Executive Officer. In July 2007, he was promoted to President. Prior to that, in February 2006, Guthart assumed the role of Chief Operating Officer. Prior to joining Intuitive, Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Guthart is currently a member of the Board of Directors of Affymetrix, Inc. He received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology.

Bill Valle is Executive Vice President of Fresenius Medical Care North America (FMCNA) and President of Fresenius Medical Services (FMS), the largest division of FMCNA. He is responsible for the successful management of more than 2,150 outpatient facilities, 1,400 inpatient programs, and 800 home dialysis programs across the U.S. Approximately 165,000 dialysis patients receive life-sustaining dialysis therapy in these facilities. Bill previously served as President of Fresenius Medical Care Integrated Renal Services. In that capacity, he led several of the organization’s vital business functions, integrating them into a high performance renal network that can improve the outcomes and reduce the costs of managing renal disease. These include Fresenius Vascular Care, FreseniusRx, Spectra Laboratories, FMS Business Development, FMS Inpatient Services and FMS Real Estate and Construction Services. Prior to joining FMCNA, Bill had 22 years of experience in the dialysis industry, serving in executive roles in sales, marketing and business development, as well as ownership in several private dialysis centers.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.